Ticker Details
Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
IPO Date:	October 7, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$494.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.33 | 3.21%
Avg Daily Range (30 D):	$0.13 | 3.67%
Avg Daily Range (90 D):	$0.13 | 3.97%

Institutional Daily Volume
Avg Daily Volume:	.76M
Avg Daily Volume (30 D):	2M
Avg Daily Volume (90 D):	1.75M

Trade Size
Avg Trade Size (Sh.):	162
Avg Trade Size (Sh.) (30 D):	191
Avg Trade Size (Sh.) (90 D):	162

Institutional Trades
Total Institutional Trades:	1,194
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$4.5M
Avg Institutional Trade (90 D):	$3.73M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.49M
Avg Closing Trade (30 D):	$1.02M
Avg Closing Trade (90 D):	$1.39M
Avg Closing Volume:	148.33K

News

Mar 20, 2026 @ 3:00 PM Aclaris Therapeutics Announces Poster on Results f... Source: Aclaris Therapeutics, Inc.

Feb 24, 2026 @ 12:00 PM Aclaris Therapeutics Initiates Phase 1b Proof-of-C... Source: Na

Nov 25, 2025 @ 1:00 PM Aclaris Therapeutics to Participate in the Piper S... Source: Will Roberts

Sep 9, 2025 @ 11:00 AM Aclaris Therapeutics Announces Late-Breaking Abstr... Source: Aclaris Therapeutics

Aug 27, 2025 @ 12:00 PM Aclaris Therapeutics to Participate in Two Septemb... Source: Will Roberts

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.53	$-.16	$-.53
Diluted EPS	$-.53	$-.16	$-.53
Revenue	$7.83M	$1.3M	$7.83M
Gross Profit	$5.74M	$.76M	$5.74M
Net Income / Loss	$-64.92M	$-19.8M	$-64.92M
Operating Income / Loss	$-76.38M	$-22.73M	$-76.38M
Cost of Revenue	$2.09M	$.53M	$2.09M
Net Cash Flow	$-4.61M	$-5.3M	$-4.61M
PE Ratio